ICU Medical (ICUI) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Integration progress and operational stability

• Recent quarters show revenue growth, margin improvement, and stronger cash generation, indicating increased business stability after a challenging integration period post-acquisition.

• Key integration challenges included supply reliability, broken quality systems, and weakened customer relationships, which took about 24 months to address.

• Investments in inventory and quality have largely been completed, with quality-related spending declining and inventory excess mostly resolved.

• ERP integration for the Smiths acquisition is nearly complete, with some short-term operational bumps being managed.

• Regulatory remediation, especially for Smiths Medical, has been a focus, with significant progress in quality systems and compliance.

Market positioning and innovation

• The pump market is highly consolidated, with a land grab underway due to upcoming market refresh cycles; innovation and breadth of portfolio are key differentiators.

• New products, such as the Plum Duo pump and LifeShield Safety software, have received positive customer feedback, emphasizing safety, accuracy, and interoperability.

• The company is positioned across high-acuity to home care environments, leveraging a full-line portfolio to capture diverse market segments.

• Revenue from new pump platforms is expected to materialize in the middle to back half of next year, given long sales and implementation cycles.

• Organic R&D investment may increase to address small portfolio gaps, with a focus on innovation in consumables and software.

Financial performance and outlook

• EBITDA margins are currently 400-500 basis points below peers, with a plan to close the gap over the next 15-24 months through synergies, cost control, and operational improvements.

• Free cash flow is improving, driven by operational gains and reduced quality/inventory spending, with future gains expected from synergies.

• Capital allocation priorities include debt reduction, with a target leverage ratio in the low-to-mid 2x range, and potential asset sales if value-accretive opportunities arise.

• Moody’s recent downgrade was attributed to leverage concerns, but cash balances have improved, and excess cash will be directed to debt paydown.

• No large-scale M&A is planned; focus remains on organic growth and possibly returning capital to shareholders once leverage targets are met.